 STOCKHOLM, Aug. 9, 2021 PRNewswire -- Calliditas Therapeutics AB Nasdaq: CALT Nasdaq Stockholm: CALTX Calliditas today announced that the U.S. Food and Drug Administration FDA has granted Fast Track Designation FTD for its lead NOX inhibitor candidate setanaxib for the treatment of patients with the chronic orphan liver disease primary biliary cholangitis PBC. Setanaxib has previously been granted orphan drug designation for PBC in the US and Europe. 